In 1992 silicone-filled breast implants were banned in America in response to concerns that they caused auto-immune and connective tissue disease. The ban triggered a torrent of litigation which proved to be unwarranted. This book reveals important differences in the way science, the law and the public regard evidence. The author maintains that, ...
In 1992 silicone-filled breast implants were banned in America in response to concerns that they caused auto-immune and connective tissue disease. The ban triggered a torrent of litigation which proved to be unwarranted. This book reveals important differences in the way science, the law and the public regard evidence. The author maintains that, as we become ever more dependent on science and technology, dangerous misconceptions about scientific evidence are becoming an increasing danger to the public good, with consequences which extend far beyond the breast implant controversy.
Publishers Weekly, 1997-09-29 A doctor examines the scientific bases for the $4.25 billion in class-action settlements by the implant industry. (Nov.)
Publishers Weekly, 1996-05-27 Angell, executive editor of the New England Journal of Medicine, explores here a preposterous situation: an industrial giant, Dow Corning, forced into Chapter 11 bankruptcy by numerous lawsuits filed on behalf of recipients of Dow's silicone breast implantsædespite the fact that medical evidence to date shows no link between implants and autoimmune disorders, cancer or any other disease. In a style that ranges from gently didactic to plodding, Angell describes the events leading up to the FDA's ban on implants, the torrent of lawsuits that followed and the implications of the verdictsæoverwhelmingly favorable to the plaintiffs and often carrying cash awards in the millions of dollarsæfor science and industry. Manufacturers have threatened to stop producing heart valves, shunts and other vital medical devices because of the threat of liability; further, suppliers of raw materials for these devices often refuse to sell to American companies for fear of ending up in an American courtroom. The author gives a clear explanation of the way science calculates risk (by considering populations, not individuals) and ably contrasts this with our judicial system, where the focus is on the individual seeking restitution. Angell is an effective champion of the scientific method and does a good job of exposing the chaos caused by a runaway tort system, but she offers no resolution to the state of affairs she describes. (July)
Alibris, the Alibris logo, and Alibris.com are registered trademarks of Alibris, Inc.
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited, Baker & Taylor, Inc., or by their respective licensors, or by the publishers, or by their respective licensors. For personal use only. All rights reserved. All rights in images of books or other publications are reserved by the original copyright holders.